

THERAKOS™ CELLEX™ PHOTOPHERESIS SYSTEM ADVANCING KNOWLEDGE ON ECP TECHNOLOGY

TIROL KLINIKEN GMBH, INNSBRUCK, AUSTRIA

This information is intended for Health Care Professionals in EU – Middle East

The goal of this practical course is to provide state of art guidance, tips and best practices on the use of the THERAKOS CELLEX™ Photopheresis System. The interactive setting allows exchanges and fosters discussion between peers.

AGENDA

DAY 1 – 20 NOVEMBER 2025

- 08:00 – 08:10 **Welcome and introduction**
Therakos International Stakeholder Engagement department
- 08:10 – 16:00 **Interactive Workshop with visit to the ECP unit**
- Welcome and Introduction
 - ECP Device
 - Device set-up and treatment: what requires special attention?
 - Device check: Timing to choose?
 - Alarms and troubleshooting
 - Q&A
- Dr Wolfgang Mayer
- 19:30 **Meeting in the lobby**
- 20:00 **Dinner**

DAY 2 – 21 NOVEMBER 2025

- 08:00 – 14:00 **Discussions with Experience Exchange**
- What to do in case of difficulties with venous access
 - Patient monitoring: what is important?
 - Q&A
 - Final Remarks and Close
- Dr Wolfgang Mayer

ECP: Extracorporeal Photopheresis



Dr Wolfgang Mayer

Senior Medical Officer, Director of the Institute's outpatient department, Tirol Kliniken GmbH

Please see the THERAKOS CELLEX Photopheresis System Operator Manual for indication, contraindications, warning, precautions and adverse events.

Brought to you by the Therakos Institute www.therakos.eu

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

[Privacy policy](#)

Follow the
Therakos Institute



Learn more about Therakos ECP Immunomodulation™ by visiting www.therakos.eu

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024 Mallinckrodt.

EU-2400193 August 2024.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.

THERAKOS™ CELLEX™ PHOTOPHERESIS SYSTEM ADVANCING KNOWLEDGE ON ECP TECHNOLOGY

TIROL KLINIKEN GMBH, INNSBRUCK, AUSTRIA

This information is intended for Health Care Professionals in EU – UK – Middle East – Saudi Arabia

The goal of this practical course is to provide state of art guidance, tips and best practices on the use of the THERAKOS CELLEX™ Photopheresis System. The interactive setting allows exchanges and fosters discussion between peers.

AGENDA

DAY 1 – 8 MAY 2025

- 08:00 – 08:10 **Welcome and introduction**
Therakos International Stakeholder Engagement department
- 08:10 – 16:00 **Interactive Workshop with visit to the ECP unit**
- Welcome and Introduction
 - ECP Device
 - Device set-up and treatment: what requires special attention?
 - Device check: Timing to choose?
 - Alarms and troubleshooting
 - Q&A
- Dr Wolfgang Mayer
- 19:30 **Meeting in the lobby**
- 20:00 **Dinner**

DAY 2 – 9 MAY 2025

- 08:00 – 14:00 **Discussions with Experience Exchange**
- What to do in case of difficulties with venous access
 - Patient monitoring: what is important?
 - Q&A
 - Final Remarks and Close
- Dr Wolfgang Mayer

ECP: Extracorporeal Photopheresis



Dr Wolfgang Mayer

Senior Medical Officer, Director of the Institute's outpatient department, Tirol Kliniken GmbH

Please see the THERAKOS CELLEX Photopheresis System Operator Manual for indication, contraindications, warning, precautions and adverse events.

Brought to you by the Therakos Institute www.therakos.eu

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

[Privacy policy](#)

Follow the
Therakos Institute



Learn more about Therakos ECP Immunomodulation™ by visiting www.therakos.eu

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2024 Mallinckrodt.

EU-2400193 August 2024.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.

THERAKOS™ CELLEX™ PHOTOPHERESIS SYSTEM ADVANCING KNOWLEDGE ON ECP TECHNOLOGY

TIROL KLINIKEN GMBH, INNSBRUCK, AUSTRIA

This information is intended for healthcare professionals based in Europe and the Middle East

The goal of this practical course is to provide state of art guidance, tips and best practices on the use of the THERAKOS CELLEX™ Photopheresis System. The interactive setting allows exchanges and fosters discussion between peers.

AGENDA

DAY 1 – 25 SEPTEMBER 2025

- 08:00 – 08:10 **Welcome and introduction**
Therakos International Stakeholder Engagement department
- 08:10 – 16:00 **Interactive Workshop with visit to the ECP unit**
- Welcome and Introduction
 - ECP Device
 - Device set-up and treatment: what requires special attention?
 - Device check: Timing to choose?
 - Alarms and troubleshooting
 - Q&A
- Dr Wolfgang Mayer
- 19:30 **Meeting in the lobby**
- 20:00 **Dinner**

DAY 2 – 26 SEPTEMBER 2025

- 08:00 – 14:00 **Discussions with Experience Exchange**
- What to do in case of difficulties with venous access
 - Patient monitoring: what is important?
 - Q&A
 - Final Remarks and Close
- Dr Wolfgang Mayer

ECP: Extracorporeal Photopheresis



Dr Wolfgang Mayer

Senior Medical Officer, Director of the Institute’s outpatient department, Tirol Kliniken GmbH

Please see the THERAKOS CELLEX Photopheresis System Operator Manual for indication, contraindications, warning, precautions and adverse events.

Brought to you by the Therakos Institute www.therakos.eu

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

Follow the
Therakos Institute



[Privacy policy](#)